Mainz Biomed N.V.
Mainz Biomed N.V. (QUCY): 1 pipeline candidate · ~6 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.6 months
D/E 0.68 · 21% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Mainz Biomed N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$46.2M
Cash
$4.5M
Quarterly Burn
$2.7M
Runway
5.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| pancalert | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$62K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 64,267 | $30K |
| susquehanna international group, llp | 18,517 | $9K |
| jane street group, llc | 16,093 | $8K |
| harbour investments, inc. | 15,730 | $7K |
| two sigma securities, llc | 12,814 | $6K |
| provenance wealth advisors, llc | 1,171 | $555 |
| bnp paribas financial markets | 600 | $284 |
| nfsg corp | 500 | $237 |
| highmark wealth management llc | 200 | $94 |
| morgan stanley | 189 | $90 |
Showing top 10 of 13 institutional holders of Mainz Biomed N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Mainz Biomed N.V.'s pipeline?
Mainz Biomed N.V. (QUCY) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mainz Biomed N.V.'s lead drug candidate?
Mainz Biomed N.V.'s most advanced tracked candidate is pancalert (Preclinical) for Pancreatic cancer.
What is Mainz Biomed N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mainz Biomed N.V. has approximately 5.6 months of cash runway.
What is Mainz Biomed N.V.'s market capitalization?
Mainz Biomed N.V.'s market capitalization is approximately $46.2M.
Who is the CEO of Mainz Biomed N.V.?
Mr. David Elliot Lazar is the chief executive officer of Mainz Biomed N.V. (QUCY).
Get the full picture on Mainz Biomed N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.